Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. (Q47886065)

6 February 2018

title

Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. (English)

1 reference

6 February 2018

author name string

P A Riedell

series ordinal

1

1 reference

6 February 2018

M R Bishop

series ordinal

2

1 reference

6 February 2018

language of work or name

English

0 references

publication date

2 October 2017

1 reference

6 February 2018

Bone Marrow Transplantation

published in

1 reference

6 February 2018

volume

53

1 reference

6 February 2018

page(s)

11-21

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

https://scigraph.springernature.com/pub.10.1038/bmt.2017.196

exact match

0 references

cites work

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Immune reconstitution after autologous hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Mantle cell lymphoma: observation to transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Targeting B-cell receptor signaling: changing the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

B-cell receptor signaling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Immune checkpoint blockade in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

The multifaceted role of mTOR in cellular stress responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Translational medicine in action: anti-CD20 therapy in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

Guidelines for the investigation and management of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2017.196

7 January 2021

Identifiers

DOI

10.1038/BMT.2017.196

1 reference

6 February 2018

PubMed ID

28967896

1 reference

6 February 2018